Harmony Biosciences Holdings, Inc.
Every calculator, already run for HRMY
Open the full toolkit →You have the numbers on HRMY. Get the argument.
A written report on which of these readings actually decide the outcome for Harmony Biosciences Holdings, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
11 analysts covering HRMYAnalyst Price Target Disagreement for Harmony Biosciences Holdings, Inc.
Wall Street's bull case implies +64% from the current price; the bear case implies -30%. A 94% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for HRMY
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under…
HRMY — frequently asked
Is HRMY a buy right now?
Wall Street's consensus rating on Harmony Biosciences Holdings, Inc. is Buy across 11 analysts, with a mean price target of $47.36 (+11% vs. the current $42.63). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is HRMY overvalued?
HRMY trades at 13.8x trailing earnings, against a DCF fair value of $69 per share. The current price implies -0% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is HRMY's next earnings date?
Harmony Biosciences Holdings, Inc. is next scheduled to report earnings around Nov 3, 2026. A full HRMY research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Harmony Biosciences Holdings, Inc.?
Analysts covering Harmony Biosciences Holdings, Inc. (HRMY) range from a bear-case target of $30.00 to a bull-case high of $70.00, with a mean consensus target of $47.36 across 11 analysts. The spread of $40.00 (94% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Harmony Biosciences Holdings, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Harmony Biosciences Holdings, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full HRMY research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Harmony Biosciences Holdings, Inc., in minutes. 3 free reports included with every account — no credit card required.